Home » Topics » Regulatory » EMA

EMA
RSS

EMA delays review of Flutiform MAA

Oct. 19, 2011

Lux Biosciences withdraws Luveniq MAA

Oct. 19, 2011

EMA confirms design of Intercell's planned phase II/III trial of Pseudomonas aeruginosa vaccine

Oct. 13, 2011

EMA recommends new orphan designation for 4SC-201

Oct. 13, 2011

EMA accepts MAA for IB-1001

Oct. 4, 2011

Aegerion gives update on European filing for lomitapide

Sep. 30, 2011

CHMP recommends approval of Prevanar 13 for new indication

Sep. 28, 2011

CHMP issues opinion on new indication for Avastin

Sep. 28, 2011

CHMP recommends approval of Alimta for new indication

Sep. 27, 2011

FDA approves new indication for Soliris

Sep. 27, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...